Skip to main content

Inrebic Dosage

Medically reviewed by Drugs.com. Last updated on Dec 3, 2021.

Generic name: FEDRATINIB HYDROCHLORIDE 100mg
Dosage form: capsule

Recommended Dosage

Conduct baseline testing of thiamine (Vitamin B1) levels prior to initiation of INREBIC [see Dosage and Administration (2.2), Warnings and Precautions (5.1)].

The recommended dosage of INREBIC is 400 mg taken orally once daily for patients with a baseline platelet count of greater than or equal to 50 × 109/L.

INREBIC may be taken with or without food. Administration with a high fat meal may reduce the incidence of nausea and vomiting.

Modify the dose for patients using concomitant strong CYP3A4 inhibitors, and in patients with severe renal impairment (creatinine clearance (CLcr) 15 mL/min to 29 mL/min) [see Dosage and Administration (2.3, 2.4)].

If a dose of INREBIC is missed, the next scheduled dose should be taken the following day.

Patients that are on treatment with ruxolitinib before the initiation of INREBIC must taper and discontinue according to the ruxolitinib prescribing information.

Monitoring for Safety

Obtain the following blood tests prior to starting treatment with INREBIC, periodically during treatment, and as clinically indicated [see Warnings and Precautions (5.1, 5.2, 5.4, 5.5)]:

Thiamine (Vitamin B1) level
Complete blood count with platelets
Creatinine and BUN
Hepatic panel
Amylase and lipase

Dose Modifications with Concomitant Use of Strong CYP3A4 Inhibitors

Reduce INREBIC dose when administering with strong CYP3A4 inhibitors to 200 mg once daily.

In cases where coadministration with a strong CYP3A4 inhibitor is discontinued, INREBIC dosage should be increased to 300 mg once daily during the first two weeks after discontinuation of the CYP3A4 inhibitor, and then to 400 mg once daily thereafter as tolerated [see Drug Interactions (7.1)].

Dose Modifications for Severe Renal Impairment

Reduce INREBIC dose to 200 mg once daily in patients with severe renal impairment (creatinine clearance (CLcr) 15 mL/min to 29 mL/min as estimated by Cockcroft-Gault (C-G) equation).

Dose Modifications for Adverse Reactions

Modify dose for hematologic and nonhematologic adverse reactions per Table 1 and Table 2. Discontinue INREBIC in patients unable to tolerate a dose of 200 mg daily. See Warnings and Precautions for other mitigating strategies.

Table 1: Dose Modifications for Hematologic Adverse Reactions

Hematologic Adverse Reactions

Dose Reduction

Grade 4 Thrombocytopenia or
Grade 3 Thrombocytopenia with active bleeding

Interrupt dose until resolved to Grade 2 or lower or baseline. Restart dose at 100 mg daily below the last given dose.

Grade 4 Neutropenia

Interrupt dose until resolved to Grade 2 or lower or baseline. Restart dose at 100 mg daily below the last given dose.

Consider dose reductions for patients who become transfusion-dependent during treatment with INREBIC.

Table 2: Dose Reductions for Nonhematologic Adverse Reactions

Nonhematologic Adverse Reactions

Dose Reduction

Grade 3 or higher Nausea, Vomiting, or Diarrhea not responding to supportive measures within 48 hours

Interrupt dose until resolved to Grade 1 or lower or baseline. Restart dose at 100 mg daily below the last given dose.

Grade 3 or higher ALT, AST, or Bilirubin

Interrupt dose until resolved to Grade 1 or lower or baseline. Restart dose at 100 mg daily below the last given dose.
Monitor ALT, AST, and bilirubin (total and direct) more frequently following the dose reduction. If reoccurrence of a Grade 3 or higher elevation, discontinue treatment with INREBIC.

Grade 3 or higher Other Nonhematologic Toxicities

Interrupt dose until resolved to Grade 1 or lower or baseline. Restart dose at 100 mg daily below the last given dose.

Management of Thiamine Levels and Wernicke's Encephalopathy (WE)

Assess thiamine levels and nutritional status prior to starting INREBIC and periodically during treatment and as clinically indicated. Do not start INREBIC in patients with thiamine deficiency; replete thiamine prior to treatment initiation and during treatment if thiamine levels are low. If Wernicke's encephalopathy is suspected, immediately discontinue treatment with INREBIC and initiate parenteral thiamine treatment. Monitor until symptoms resolve or improve and thiamine levels normalize [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.